Summary.-The antitumour agent 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC) was found to inhibit competitively the low-Km cyclic AMP phosphodiesterase activity in an ammonium-sulphate-precipitable fraction of the 2,000g supernatant of rat liver. With substrate concentration at 0-25 [M, 150 was 790 /tM for DTIC and 350 tM for theophylline. DTIC at 2 mm more than doubled the cAMP response to glucagon in hepatocytes and to adrenaline in MH1Cj hepatoma cells, indicating that it also exerts its inhibitory effect on the phosphodiesterase in intact cells. The possible contribution of the phosphodiesterase inhibition to the growthinhibitory and cytotoxic effects of DTIC is discussed.
UNDER CERTAIN CONDITIONS, high intracellular concentrations of cyclic 3',5'-adenosine monophosphate (cAMP) inhibit cell proliferation. Although the role of this nucleotide in the physiological growth regulation is still unclear and probably diverse, it has been firmly established that in several cultured cell lines proliferation is inhibited if the intracellular level of cAMP is artificially raised (Pastan et al., 1975; Friedman, 1976) . It is conceivable, therefore, that drugs altering cAMP levels might contribute to pharmacological control of cancer-cell proliferation.
There is some evidence that certain antitumour drugs already in clinical use interfere with cAMP metabolism. Thus, Tisdale & Phillips (1975a, b) have shown that several alkylating antitumour agents increase intracellular cAMP in Walker carcinoma cells in vitro, probably owing to inhibition by these drugs of the low-Km form of the phosphodiesterase that breaks down cAMP (Tisdale, 1974) . Recently, Rudolph et al. (1977) and Kotani et al. (1978) have shown that colchicine and the vinca alkaloids vincristine and vinblastine also raise cellular cAMP levels in leucocytes and lymphoma cells.
We here show that another antitumour agent, 5 -(3,3 -dimethyl -1 -triazeno)imidazole-4-carboxamide (DTIC) is able to inhibit the low-Km form of cAMP phosphodiesterase of rat liver, and to amplify the cAMP response of isolated intact hepatocytes and cultured hepatoma cells to hormones. Assay of cAMP phosphodiesterase.-Adult male Wistar rat liver was homogenized with a Potter-Elvehjem glass-teflon homogenizer in a buffer containing 100mM tris-HCl (pH 7 5) and 4mM MgCl2. The homogenate was centrifuged at 2000 g for 10 min, and the supernatant was treated with (NH4)2S04 to give 55%. The fraction precipitated by (NH4)2S04 was dissolved by dialysing it overnight with two changes against the tris buffer, and stored in aliquots at -80°C. Unless otherwise stated, this preparation was used as the enzyme source in the phosphodiesterase reactions.
The phosphodiesterase assay was carried out essentially as described previously (Christoffersen et al., 1973) . The reaction was run at 30'C in a final volume of 400 ,ul in 100mM tris-HCl (pH 7.5) and 4mM MgCi2. The enzyme activity was measured at various times at various concentrations of cAMP, with [3H]cAMP (-10,000 ct/incubate). The amount of enzyme per incubate was varied between 75 and 1500 ,tg protein, according to the substrate concentration. The reaction was terminated by heating at 95°C for 2 min.
[14C]cAMP (-5000 ct/min/tube) was added for recovery determination. The cAMP remaining after the incubation was isolated by paper chromatography as previously described (Christoffersen et al., 1973) and counted by liquid scintillation. In kinetic analyses, estimation of initial reaction velocity was based on several incubation times and extrapolating to zero.
Cells8 used.-Previously described procedures were used for hepatocyte isolation (Berg et al., 1972; Seglen, 1972; Christoffersen & Berg, 1974) and incubation (Christoffersen & Berg, 1975 The cells were cultured as incomplete monolayers in Falcon plastic flasks (75 cm2), in lOml Dulbecco's modified Eagle's medium, supplemented with 10% horse serum, 2-5% foetal calf serum, penicillin (100 u/ml), streptomycin (0-1 mg/ml) and nystatin (60 u/ml). Medium change was at 3-4 days and subculturing at 7 days. The cells were used for experiments 7 days after seeding, when they were nearly fully grown. Incubations were done in the culture medium described above, and the reactions were stopped by addition of 5% trichloroacetic acid, after rapid removal of medium and washing (twice) of the cell layers with saline.
Determination of cAMP.-The samples were centrifuged, and the trichloroacetic acid in the supernatants was neutralized with CaCO3, as described by Tihon et al. (1977) . cAMP was measured by a radioimmunoassay (Steiner et al., 1969) using acetylation of the samples (Harper & Brooker, 1975; Frandsen & Krishna, 1976) and acetylated [3H]cAMP as ligand (Skomedal et al., 1977) .
Other procedures.-Protein was determined by the method of Lowry. Cells were counted with a Burker haemacytometer.
RESULTS

Effects on phosphodiesterase
As shown in Table I , DTIC inhibited the breakdown of cAMP in a rat liver 40,00Og supernatant, when a low concentration (0-25 ,tM) of substrate was used to allow measurement of the low-Km form(s) of the cAMP phosphodiesterase. DTIC did not seem to affect the high-Km form, as no inhibition was seen with the use of 2mM cAMP as substrate (Table I) .
DTIC inhibited the low-Km phospho- Some characteristics of the inhibition by DTIC are given in Fig. 2 A-C. Fig. 2B shows dose-response curves for DTIC and theophylline, using 0 25 MM of substrate. 5000 inhibition was obtained at 790 /LM for DTIC and at 350 /tM for theophylline. The inhibition by DTIC apparently did not require a preincubation period, as it was evident from the beginning of the incubation ( Fig. 2A) . This differs from the phosphodiesterase inhibition produced by the alkylating agent chlorambucil, which involves a progressive time-dependent change of the enzyme in presence of the drug (Tisdale, 1974 (Beal et al., 1976) , and the inhibition was immediately manifest. Control experiments showed that DTIC exposed to sunlight or UV for 1 h inhibited the phosphodiesterase essentially in the same way as in the standard experiments.
Effects on intact cells
To test whether DTIC also influences the phosphodiesterase in intact cells, we investigated its effect on cAMP accumulation in response to hormones in primary hepatocyte suspensions and MH1C1 hepatoma cell monolayers in culture (Table II) .
In hepatocyte suspensions, the presence Similarly, in MH1Cj hepatoma cells, pretreatment (10 min) with 2mM DTIC or theophylline led to a 2-3-fold amplification of the cAMP response to adrenaline (50 ,kM, 60sec exposure). In these experiments the effect of DTIC or theophylline alone on cAMP levels (i.e. without subsequent adrenaline exposure) was not examined in detail, but later studies (Haffner & Christoffersen, unpublished) have shown significantly raised cAMP in MH1C1 cells after DTIC or other phosphodiesterase inhibitors.
DISCUSSION
These results show that the antitumour agent DTIC is a competitive inhibitor of the low-Km form of cAMP phosphodiesterase, and the ability of DTIC to amplify hormone effects on cAMP accumulation in hepatocytes and hepatoma cells indicates thatthe inhibition ofthe phosphodiesterase is also manifested in intact cells.
Since about 800 [kM was necessary to achieve 50% inhibition of the phosphodiesterase, DTIC is apparently not a particularly potent inhibitor. However, its potency was of about the same order as that of the classical (though not very strong) phosphodiesterase inhibitor theophylline, both as inhibitor in the cell-free phosphodiesterase assay and in augmenting the cAMP response to glucagon and adrenaline in intact cells.
It is not clear whether this phosphodiesterase inhibition plays any role in the antitumour and growth-inhibitory effects of DTIC. The mechanism of action of this drug remains obscure, despite much study (Loo, 1975; Loo et al., 1976; Bono, 1976; Beal et al., 1976) . Several theories have been proposed, including purine antimetabolite action (Loo et al., 1968) , release of an alkylating methyl radical (Skibba et al., 1970; Gerulath & Loo, 1972) and interaction with SH-groups (Yamamoto, 1969) . However, none of these hypotheses have so far gained definitive support. The present study of the effects of DTIC on phosphodiesterase and cAMP in liver was provoked by the growthinhibitory and differentiating effect of cAMP on many cell types (Pastan et al., 1975; Friedman, 1976) , and by the fact that several other imidazole and imidazolidinone derivatives have been shown to be cAMP phosphodiesterase inhibitors (Chasin & Harris, 1976) . DTIC inhibits cells in G1 as well as G2 (Bono, 1976; Gerulath et al., 1974) , which could be compatible with a cAMP-mediated effect (Friedman et al., 1976) . Furthermore, in cultured mouse neuroblastoma cells, treatment with DTIC (10 jug/ml) causes increased activity of tyrosine hydroxylase, choline acetyltransferase and acetylcholinesterase (Culver et al., 1977) . These effects of DTIC, which may be considered as manifestations of biochemical differentiation of the neuroblastoma cells, are also seen after dibutyryl cAMP administration (Prasad, 1975) . However, the increase of these enzyme activities after DTIC were not accompanied by any demonstrable increase in cAMP level or inhibition of phosphodiesterase activity in the study by Culver et al. (1977) There is some evidence that certain metabolites of DTIC may be responsible for the growth-inhibitory effects of the drug. DTIC is partly demethylated in vivo to yield the monomethyl derivative (MTIC; Skibba et al., 1970) , which is also growth-inhibitory, although it is unclear whether the amount formed is sufficient to account for the effects of DTIC (Beal et al., 1976) . The role of other degradation products formed by photodecomposition and possibly also in vivo has been discussed (Loo, 1975; Loo et al., 1976) . It will thus be of interest to examine the effect on cAMP metabolism of various metabolites and analogues of DTIC. Further investigations are necessary to clarify whether cAMP is involved in any aspect of the cytotoxic effect of DTIC. Such studies might also contribute to the understanding of the potential in cancer treatment of substances that act on the cAMP system. This work was supported by the Norwegian Cancer Society (Landsforeningen mot Kreft) and the Norwegian Council for Science and the Humanities.
